Acarix AB (publ) (ACARIX.ST)
SEK 0.22
(-2.47%)
SEK 0.22
(-2.47%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -77.83 Million SEK | -0.44% |
| 2022 | -77.49 Million SEK | -49.6% |
| 2021 | -51.8 Million SEK | -24.68% |
| 2020 | -41.54 Million SEK | 10.57% |
| 2019 | -46.45 Million SEK | -9.91% |
| 2018 | -42.27 Million SEK | -41.96% |
| 2017 | -29.77 Million SEK | 38.28% |
| 2016 | -48.24 Million SEK | -289.25% |
| 2015 | -12.39 Million SEK | 35.48% |
| 2014 | -19.2 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -14.93 Million SEK | 32.33% |
| 2024 Q2 | -16.66 Million SEK | -11.59% |
| 2023 Q4 | -22.06 Million SEK | -27.6% |
| 2023 FY | -77.83 Million SEK | -0.44% |
| 2023 Q2 | -22 Million SEK | -33.53% |
| 2023 Q3 | -17.29 Million SEK | 21.42% |
| 2023 Q1 | -16.47 Million SEK | 27.12% |
| 2022 Q2 | -18.45 Million SEK | -23.52% |
| 2022 FY | -77.49 Million SEK | -49.6% |
| 2022 Q1 | -14.94 Million SEK | 7.88% |
| 2022 Q4 | -22.61 Million SEK | -5.27% |
| 2022 Q3 | -21.48 Million SEK | -16.37% |
| 2021 FY | -51.8 Million SEK | -24.68% |
| 2021 Q2 | -13.09 Million SEK | -11.69% |
| 2021 Q3 | -10.69 Million SEK | 18.32% |
| 2021 Q4 | -16.22 Million SEK | -51.72% |
| 2021 Q1 | -11.72 Million SEK | -2.73% |
| 2020 Q3 | -8.88 Million SEK | 14.53% |
| 2020 FY | -41.54 Million SEK | 10.57% |
| 2020 Q4 | -11.41 Million SEK | -28.5% |
| 2020 Q2 | -10.39 Million SEK | 3.93% |
| 2020 Q1 | -10.81 Million SEK | -8.29% |
| 2019 Q3 | -11.32 Million SEK | 8.32% |
| 2019 Q4 | -9.98 Million SEK | 11.8% |
| 2019 FY | -46.45 Million SEK | -9.91% |
| 2019 Q1 | -12.79 Million SEK | -6.59% |
| 2019 Q2 | -12.35 Million SEK | 3.49% |
| 2018 Q1 | -7.96 Million SEK | 37.43% |
| 2018 FY | -42.27 Million SEK | -41.96% |
| 2018 Q4 | -12 Million SEK | 5.79% |
| 2018 Q3 | -12.74 Million SEK | -33.64% |
| 2018 Q2 | -9.53 Million SEK | -19.75% |
| 2017 Q1 | -3.49 Million SEK | 76.63% |
| 2017 Q2 | -6.5 Million SEK | -86.37% |
| 2017 Q3 | -7.04 Million SEK | -8.31% |
| 2017 FY | -29.77 Million SEK | 38.28% |
| 2017 Q4 | -12.72 Million SEK | -80.55% |
| 2016 Q3 | -29.78 Million SEK | -1416.65% |
| 2016 Q1 | -1.54 Million SEK | -1.45% |
| 2016 FY | -48.24 Million SEK | -289.25% |
| 2016 Q4 | -14.94 Million SEK | 49.83% |
| 2016 Q2 | -1.96 Million SEK | -27.2% |
| 2015 Q4 | -1.52 Million SEK | 0.0% |
| 2015 FY | -12.39 Million SEK | 35.48% |
| 2014 FY | -19.2 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ADDvise Group AB (publ) | 103.5 Million SEK | 175.207% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 175.207% |
| Arcoma AB | 2.56 Million SEK | 3135.842% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 43.751% |
| BICO Group AB (publ) | -835.7 Million SEK | 90.686% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 411.643% |
| CellaVision AB (publ) | 130.3 Million SEK | 159.734% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 2.448% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -166.694% |
| C-Rad AB (publ) | 35.52 Million SEK | 319.086% |
| Duearity AB (publ) | -26.19 Million SEK | -197.209% |
| Dignitana AB (publ) | -17.36 Million SEK | -348.304% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 17.891% |
| Getinge AB (publ) | 2.41 Billion SEK | 103.227% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | -14.507% |
| Iconovo AB (publ) | -45.89 Million SEK | -69.607% |
| Integrum AB (publ) | 4.03 Million SEK | 2030.302% |
| Luxbright AB (publ) | -25.37 Million SEK | -206.753% |
| Mentice AB (publ) | -2.81 Million SEK | -2663.188% |
| OssDsign AB (publ) | -130.49 Million SEK | 40.35% |
| Paxman AB (publ) | 8.33 Million SEK | 1034.442% |
| Promimic AB (publ) | -9.22 Million SEK | -744.058% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 51.337% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -40.036% |
| ScandiDos AB (publ) | -14.64 Million SEK | -431.433% |
| Sectra AB (publ) | 428.38 Million SEK | 118.17% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -30.576% |
| Senzime AB (publ) | -134.14 Million SEK | 41.976% |
| SpectraCure AB (publ) | -20.44 Million SEK | -280.798% |
| Stille AB | 26.64 Million SEK | 392.123% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 97.979% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 184.773% |